Abstract
Angiogenesis is an important mechanism of immune evasion and there are emerging data suggesting a benefit from combining immune checkpoint inhibitors (ICIs) with anti-angiogenic therapies. We evaluated the combination of atezolizumab and ramucirumab in patients (pts) with previously treated non-small cell lung cancer (NSCLC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
